Zacks Research Predicts Medifast FY2028 Earnings

Medifast Inc (NYSE:MED) – Analysts at Zacks Research issued their FY2028 earnings per share estimates for shares of Medifast in a research note issued to investors on Tuesday, March 10th. Zacks Research analyst Team anticipates that the specialty retailer will earn ($1.83) per share for the year. The consensus estimate for Medifast’s current full-year earnings is $0.51 per share.

A number of other equities research analysts have also weighed in on the stock. Wall Street Zen lowered shares of Medifast from a “hold” rating to a “sell” rating in a report on Saturday, February 21st. Weiss Ratings reissued a “sell (d)” rating on shares of Medifast in a research note on Thursday, January 22nd. Finally, Stephens cut their price target on shares of Medifast from $15.00 to $12.00 and set an “equal weight” rating for the company in a research report on Thursday, February 19th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Reduce” and an average target price of $12.00.

Medifast Price Performance

Shares of NYSE MED opened at $10.12 on Wednesday. Medifast has a one year low of $10.04 and a one year high of $15.46. The firm’s 50 day simple moving average is $11.06 and its two-hundred day simple moving average is $12.01. The stock has a market capitalization of $111.22 million, a P/E ratio of -5.92 and a beta of 0.52.

Medifast (NYSE:MED) last announced its quarterly earnings data on Tuesday, February 17th. The specialty retailer reported ($0.55) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.21. The company had revenue of $75.10 million for the quarter, compared to analysts’ expectations of $71.40 million. Medifast had a negative return on equity of 4.27% and a negative net margin of 4.84%.Medifast has set its FY 2026 guidance at -2.750–1.55 EPS and its Q1 2026 guidance at -0.700–0.15 EPS.

Institutional Investors Weigh In On Medifast

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. PNC Financial Services Group Inc. boosted its position in Medifast by 261.8% during the 2nd quarter. PNC Financial Services Group Inc. now owns 2,001 shares of the specialty retailer’s stock valued at $28,000 after buying an additional 1,448 shares during the period. BNP Paribas Financial Markets grew its stake in shares of Medifast by 103.1% in the third quarter. BNP Paribas Financial Markets now owns 2,338 shares of the specialty retailer’s stock worth $32,000 after purchasing an additional 1,187 shares during the last quarter. Quantbot Technologies LP bought a new stake in shares of Medifast in the third quarter worth about $37,000. Intesa Sanpaolo Wealth Management purchased a new position in Medifast during the 4th quarter valued at about $47,000. Finally, State of Wyoming purchased a new position in Medifast during the 4th quarter valued at about $59,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

Medifast, Inc (NYSE: MED) is a health and wellness company specializing in clinically supported weight-loss, weight-management and healthy living products and services. Through its OPTAVIA brand, the company offers a range of meal replacement products, snacks, supplements and coaching programs designed to support metabolic health and sustainable lifestyle changes. Medifast markets its products directly to consumers via a network of independent distributors—known as OPTAVIA Coaches—who provide personalized guidance and support throughout the client’s weight‐loss journey.

Founded in 1980 by William Vitale and headquartered in Baltimore, Maryland, Medifast has grown into a nationally recognized provider of nutrition and weight‐management solutions.